Literature DB >> 18345325

Effect of inhibition of prostaglandin E2 production on pancreatic infection in experimental acute pancreatitis.

Andre S Matheus1, Ana Maria M Coelho, Sandra Sampietre, Rosely Patzina, Jose Jukemura, Jose Eduardo M Cunha, Marcel C C Machado.   

Abstract

OBJECTIVE: Acute pancreatitis is one the important causes of systemic inflammatory response syndrome (SIRS). SIRS results in gut barrier dysfunction that allows bacterial translocation and pancreatic infection to occur. Indomethacin has been used to reduce inflammatory process and bacterial translocation in experimental models. The purpose of this study was to determine the effect of inhibition of prostaglandin E2 (PGE2) production on pancreatic infection.
MATERIALS AND METHODS: An experimental model of severe acute pancreatitis (AP) was utilized. The animals were divided into three groups: sham (surgical procedure without AP induction); pancreatitis (AP induction); and indomethacin (AP induction plus administration of 3 mg/kg of indomethacin). Serum levels of interleukin (IL)-6 and IL-10, PGE2, and tumor necrosis factor (TNF)-alpha were measured 2 h after the induction of AP. We analyzed the occurrence of pancreatic infection with bacterial cultures performed 24 h after the induction of AP. The occurrence of pancreatic infection (considered positive when the CFU/g was >105), pancreatic histologic analysis, and mortality rate were studied.
RESULTS: In spite of the reduction of IL-6, IL-10, and PGE2 levels in the indomethacin group, TNF-alpha level, bacterial translocation, and pancreatic infection were not influenced by administration of indomethacin. The inhibition of PGE2 production did not reduce pancreatic infection, histologic score, or mortality rate.
CONCLUSION: The inhibition of PGE2 production was not able to reduce the occurrence of pancreatic infection and does not have any beneficial effect in this experimental model. Further investigations will be necessary to discover a specific inhibitor that would make it possible to develop an anti-inflammatory therapy.

Entities:  

Keywords:  bacterial translocation; experimental acute pancreatitis; indomethacin; pancreatic infection; prostaglandin E2

Year:  2007        PMID: 18345325      PMCID: PMC2225519          DOI: 10.1080/13651820701646214

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  30 in total

Review 1.  Cytokine storm in acute pancreatitis.

Authors:  Rohit Makhija; Andrew N Kingsnorth
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

Review 2.  Bacterial infection of pancreatic necrosis: role of bacterial translocation, impact of antibiotic treatment.

Authors:  R Isenmann; H G Beger
Journal:  Pancreatology       Date:  2001       Impact factor: 3.996

3.  Bacterial translocation in acute pancreatitis.

Authors:  Andrew Thomson
Journal:  J Gastroenterol Hepatol       Date:  2003-10       Impact factor: 4.029

4.  Relationship between plasma cytokine concentration and multiple organ failure in patients with acute pancreatitis.

Authors:  M Hirota; F Nozawa; A Okabe; M Shibata; T Beppu; S Shimada; H Egami; Y Yamaguchi; S Ikei; T Okajima; K Okamoto; M Ogawa
Journal:  Pancreas       Date:  2000-08       Impact factor: 3.327

5.  The effects of prostaglandin E1 on the microperfusion of the pancreas during acute necrotizing pancreatitis in rats.

Authors:  Kadir Yücel; Etem Alhan; Uzer Küçüktülü; Metin Piri; Cengiz Erçin; Orhan Deger
Journal:  Hepatogastroenterology       Date:  2002 Mar-Apr

6.  Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis.

Authors:  Thomas Foitzik; H G Hotz; B Hotz; F Wittig; Heinz J Buhr
Journal:  Hepatogastroenterology       Date:  2003 Jul-Aug

7.  Role of COX-2 in microcirculatory disturbance in experimental pancreatitis.

Authors:  Wen-Wei Yan; Zong-Guang Zhou; You-Dai Chen; Hong-Kai Gao
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

8.  Time course of production of cytokines and prostaglandin E2 by macrophages isolated after thermal injury and bacterial translocation.

Authors:  R Fukushima; J W Alexander; J Z Wu; J X Mao; K Szczur; A M Stephens; J D Ogle; C K Ogle
Journal:  Circ Shock       Date:  1994-03

Review 9.  Inflammatory mediators in acute pancreatitis.

Authors:  L J Formela; S W Galloway; A N Kingsnorth
Journal:  Br J Surg       Date:  1995-01       Impact factor: 6.939

10.  Pathogenesis and prevention of early pancreatic infection in experimental acute necrotizing pancreatitis.

Authors:  T Foitzik; C Fernández-del Castillo; M J Ferraro; K Mithöfer; D W Rattner; A L Warshaw
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

View more
  4 in total

1.  Vasoactive intestinal peptide promotes gut barrier function against severe acute pancreatitis.

Authors:  Lu Zhongkai; Ye Jianxin; Chen Weichang
Journal:  Mol Biol Rep       Date:  2011-07-03       Impact factor: 2.316

2.  Infusion of Bone Marrow Mesenchymal Stem Cells Attenuates Experimental Severe Acute Pancreatitis in Rats.

Authors:  Hang Zhao; Zhiying He; Dandan Huang; Jun Gao; Yanfang Gong; Hongyu Wu; Aifang Xu; Xiangjun Meng; Zhaoshen Li
Journal:  Stem Cells Int       Date:  2016-09-18       Impact factor: 5.443

3.  Rectal Indomethacin Does Not Mitigate the Systemic Inflammatory Response Syndrome in Acute Pancreatitis: A Randomized Trial.

Authors:  Jorge D Machicado; Rawad Mounzer; Pedram Paragomi; Ioannis Pothoulakis; Phil A Hart; Darwin L Conwell; Enrique de-Madaria; Phil Greer; Dhiraj Yadav; David C Whitcomb; Peter J Lee; Alice Hinton; Georgios I Papachristou
Journal:  Clin Transl Gastroenterol       Date:  2021-10-27       Impact factor: 4.488

4.  Increased cyclooxygenase-2 and nuclear factor-κB/p65 expression in mouse hippocampi after systemic administration of tetanus toxin.

Authors:  Bing Chun Yan; Yong Hwan Jeon; Joon Ha Park; In Hye Kim; Jeong-Hwi Cho; Ji Hyeon Ahn; Bai Hui Chen; Hyun-Jin Tae; Jae-Chul Lee; Ji Yun Ahn; Dong Won Kim; Jun Hwi Cho; Moo-Ho Won; Seongkweon Hong
Journal:  Mol Med Rep       Date:  2015-10-26       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.